These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27306979)

  • 1. Demonstration of the functional impact of vasopressin signaling in the thick ascending limb by a targeted transgenic rat approach.
    Mutig K; Borowski T; Boldt C; Borschewski A; Paliege A; Popova E; Bader M; Bachmann S
    Am J Physiol Renal Physiol; 2016 Aug; 311(2):F411-23. PubMed ID: 27306979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL.
    Mutig K; Paliege A; Kahl T; Jöns T; Müller-Esterl W; Bachmann S
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1166-77. PubMed ID: 17626156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of renal Na-(K)-Cl cotransporters by vasopressin.
    Bachmann S; Mutig K
    Pflugers Arch; 2017 Aug; 469(7-8):889-897. PubMed ID: 28577072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
    Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
    PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of renal Na-K-2Cl cotransporter 2 in obese diabetes mellitus via a vasopressin receptor 2-dependent pathway.
    Sakai K; Yamazaki O; Ishizawa K; Tamura Y; Wang Q; Ueno M; Hayama Y; Fujigaki Y; Shibata S
    Biochem Biophys Res Commun; 2020 Apr; 524(3):710-715. PubMed ID: 32035616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.
    Robben JH; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2006 Aug; 291(2):F257-70. PubMed ID: 16825342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the bumetanide-sensitive Na+,K+,2Cl- cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner.
    Mutig K; Kahl T; Saritas T; Godes M; Persson P; Bates J; Raffi H; Rampoldi L; Uchida S; Hille C; Dosche C; Kumar S; Castañeda-Bueno M; Gamba G; Bachmann S
    J Biol Chem; 2011 Aug; 286(34):30200-10. PubMed ID: 21737451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG
    Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.
    Juul KV; Bichet DG; Nielsen S; Nørgaard JP
    Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin lowers renal epoxyeicosatrienoic acid levels by activating soluble epoxide hydrolase.
    Boldt C; Röschel T; Himmerkus N; Plain A; Bleich M; Labes R; Blum M; Krause H; Magheli A; Giesecke T; Mutig K; Rothe M; Weldon SM; Dragun D; Schunck WH; Bachmann S; Paliege A
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1198-F1210. PubMed ID: 27681558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney.
    Fenton RA; Brønd L; Nielsen S; Praetorius J
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F748-60. PubMed ID: 17553938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Losartan decreases vasopressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure.
    Torp M; Brønd L; Hadrup N; Nielsen JB; Praetorius J; Nielsen S; Christensen S; Jonassen TE
    Acta Physiol (Oxf); 2007 Aug; 190(4):339-50. PubMed ID: 17635349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group VIA phospholipase A2 is a target for vasopressin signaling in the thick ascending limb.
    Paliege A; Roeschel T; Neymeyer H; Seidel S; Kahl T; Daigeler AL; Mutig K; Mrowka R; Ferreri NR; Wilson BS; Himmerkus N; Bleich M; Bachmann S
    Am J Physiol Renal Physiol; 2012 Apr; 302(7):F865-74. PubMed ID: 22218592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenine acts in the kidney as a signaling factor and causes salt- and water-losing nephropathy: early mechanism of adenine-induced renal injury.
    Dos Santos IF; Sheriff S; Amlal S; Ahmed RPH; Thakar CV; Amlal H
    Am J Physiol Renal Physiol; 2019 Apr; 316(4):F743-F757. PubMed ID: 30623725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl-beta-cyclodextrin induces vasopressin-independent apical accumulation of aquaporin-2 in the isolated, perfused rat kidney.
    Russo LM; McKee M; Brown D
    Am J Physiol Renal Physiol; 2006 Jul; 291(1):F246-53. PubMed ID: 16449354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
    Kim GH; Choi NW; Jung JY; Song JH; Lee CH; Kang CM; Knepper MA
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F702-9. PubMed ID: 18216147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.
    Zhang Y; Peti-Peterdi J; Müller CE; Carlson NG; Baqi Y; Strasburg DL; Heiney KM; Villanueva K; Kohan DE; Kishore BK
    J Am Soc Nephrol; 2015 Dec; 26(12):2978-87. PubMed ID: 25855780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus.
    Ando F
    Clin Exp Nephrol; 2021 Oct; 25(10):1051-1056. PubMed ID: 34224008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.